These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24806111)

  • 1. Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths.
    Prasad V; Bodei L; Kidd M; Modlin IM
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1825-30. PubMed ID: 24806111
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptide receptor radionuclide therapy of neuroendocrine tumours.
    Brabander T; Teunissen JJ; Van Eijck CH; Franssen GJ; Feelders RA; de Herder WW; Kwekkeboom DJ
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):103-14. PubMed ID: 26971847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.
    Hendifar AE; Delpassand ES; Kittleson MM; Tuli R
    Pancreas; 2018 Sep; 47(8):e55-e56. PubMed ID: 30113434
    [No Abstract]   [Full Text] [Related]  

  • 4. Peptide Receptor Radiotherapy Comes of Age.
    Al-Toubah T; Strosberg J
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):615-625. PubMed ID: 30098719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific biology of neuroendocrine tumors: Peptide receptors as molecular targets.
    Körner M
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):19-31. PubMed ID: 26971841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
    Bodei L; Kidd M; Prasad V; Modlin IM
    Front Horm Res; 2015; 44():198-215. PubMed ID: 26303714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 8. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
    Kwekkeboom DJ; Krenning EP
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
    Lo Russo G; Pusceddu S; Prinzi N; Imbimbo M; Proto C; Signorelli D; Vitali M; Ganzinelli M; Maccauro M; Buzzoni R; Seregni E; de Braud F; Garassino MC
    Tumour Biol; 2016 Oct; 37(10):12991-13003. PubMed ID: 27460087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy.
    Blaickner M; Baum RP
    PET Clin; 2014 Jan; 9(1):99-112. PubMed ID: 25029939
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Hicks RJ; Jackson P; Kong G; Ware RE; Hofman MS; Pattison DA; Akhurst TA; Drummond E; Roselt P; Callahan J; Price R; Jeffery CM; Hong E; Noonan W; Herschtal A; Hicks LJ; Hedt A; Harris M; Paterson BM; Donnelly PS
    J Nucl Med; 2019 Jun; 60(6):777-785. PubMed ID: 30442752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with
    Adnan A; Basu S
    J Nucl Med Technol; 2020 Mar; 48(1):36-39. PubMed ID: 31401619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapy.
    Werner RA; Brumberg J; Dierks A; Herrmann K; Biko J; Buck AK; Lapa C
    Clin Nucl Med; 2015 Mar; 40(3):263-4. PubMed ID: 25546217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint guidance on peptide receptor radionuclide therapy in neuroendocrine tumors.
    Delbeke D; Graham MM
    J Nucl Med; 2013 May; 54(5):663. PubMed ID: 23536220
    [No Abstract]   [Full Text] [Related]  

  • 15. Peptide-receptor radionuclide therapy for endocrine tumors.
    van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ
    Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
    Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
    Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addendum to the editorial "Joint guidance on peptide receptor radionuclide therapy in neuroendocrine tumors".
    Delbeke D; Graham MM
    J Nucl Med; 2013 Jul; 54(7):1170. PubMed ID: 23733924
    [No Abstract]   [Full Text] [Related]  

  • 18. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
    Bodei L; Mueller-Brand J; Baum RP; Pavel ME; Hörsch D; O'Dorisio MS; O'Dorisio TM; Howe JR; Cremonesi M; Kwekkeboom DJ; Zaknun JJ
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):800-16. PubMed ID: 23389427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and perspectives in peptide receptor radiation therapy.
    Ansquer C; Kraeber-Bodéré F; Chatal JF
    Curr Pharm Des; 2009; 15(21):2453-62. PubMed ID: 19601842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.